TG Therapeutics, Inc. Announces Presentation of Interim Results From Its Phase ... NASDAQ (press release) NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( TGTX ) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin's ... |
